[go: up one dir, main page]

EE200200498A - Asendatud 3-fenüül-5-alkoksü-1,3,4-oksadiasol-2-oon, selle valmistamine ja kasutamine hormoontundlikku lipaasi pärssivas ravimis ning seda sisaldav suhkurtõve ravim - Google Patents

Asendatud 3-fenüül-5-alkoksü-1,3,4-oksadiasol-2-oon, selle valmistamine ja kasutamine hormoontundlikku lipaasi pärssivas ravimis ning seda sisaldav suhkurtõve ravim

Info

Publication number
EE200200498A
EE200200498A EEP200200498A EEP200200498A EE200200498A EE 200200498 A EE200200498 A EE 200200498A EE P200200498 A EEP200200498 A EE P200200498A EE P200200498 A EEP200200498 A EE P200200498A EE 200200498 A EE200200498 A EE 200200498A
Authority
EE
Estonia
Prior art keywords
oxadiazol
hormone
alkoxy
phenyl
substituted
Prior art date
Application number
EEP200200498A
Other languages
English (en)
Inventor
Schoenafinger Karl
Petry Stefan
Mueller Guenter
Baringhaus Karl-Heinz
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2000110968 external-priority patent/DE10010968A1/de
Priority claimed from DE2001102265 external-priority patent/DE10102265C1/de
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of EE200200498A publication Critical patent/EE200200498A/et
Publication of EE04877B1 publication Critical patent/EE04877B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
EEP200200498A 2000-03-07 2001-02-20 Asendatud 3-fenl-5-alkoks-1,3,4-oksadiasol-2-oon, selle valmistamine ja kasutamine hormoontundlikku lipaasi p„rssivas ravimis ning seda sisaldav suhkurt?ve ravim EE04877B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE2000110968 DE10010968A1 (de) 2000-03-07 2000-03-07 Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen
DE2001102265 DE10102265C1 (de) 2001-01-18 2001-01-18 Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen
PCT/EP2001/001898 WO2001066531A1 (de) 2000-03-07 2001-02-20 Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one (und) ihre verwendung zur hemmung der hormonsensitiven lipase

Publications (2)

Publication Number Publication Date
EE200200498A true EE200200498A (et) 2004-02-16
EE04877B1 EE04877B1 (et) 2007-08-15

Family

ID=26004720

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200498A EE04877B1 (et) 2000-03-07 2001-02-20 Asendatud 3-fenl-5-alkoks-1,3,4-oksadiasol-2-oon, selle valmistamine ja kasutamine hormoontundlikku lipaasi p„rssivas ravimis ning seda sisaldav suhkurt?ve ravim

Country Status (28)

Country Link
US (1) US6369088B2 (et)
EP (1) EP1263745B1 (et)
JP (1) JP2003525931A (et)
KR (1) KR100790763B1 (et)
CN (1) CN1261419C (et)
AR (1) AR027611A1 (et)
AT (1) ATE267184T1 (et)
AU (1) AU784827B2 (et)
BR (1) BR0108974A (et)
CA (1) CA2401953A1 (et)
DE (1) DE50102325D1 (et)
DK (1) DK1263745T3 (et)
EE (1) EE04877B1 (et)
ES (1) ES2218383T3 (et)
HK (1) HK1054036B (et)
HR (1) HRP20020732A2 (et)
HU (1) HUP0302772A3 (et)
IL (1) IL151518A (et)
MX (1) MXPA02008038A (et)
NO (1) NO323483B1 (et)
NZ (1) NZ521207A (et)
PL (1) PL359702A1 (et)
PT (1) PT1263745E (et)
RU (1) RU2281283C2 (et)
SK (1) SK12752002A3 (et)
TR (1) TR200401217T4 (et)
WO (1) WO2001066531A1 (et)
YU (1) YU57802A (et)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
US6900233B2 (en) 2002-02-28 2005-05-31 Aventis Pharma Deutschland Gmbh Substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadiazol-2-ones, pharmaceutical composition and method for treating obesity thereof
DE10208987A1 (de) * 2002-02-28 2003-09-11 Aventis Pharma Gmbh Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxidiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen
US20030236288A1 (en) * 2002-02-28 2003-12-25 Karl Schoenafinger Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase
DE10208986A1 (de) * 2002-02-28 2003-09-11 Aventis Pharma Gmbh Verwendung substituierter 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one zur Herstellung von Arzneimitteln mit hemmender Wirkung an der pankreatischen Lipase
SE0203754D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203753D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
WO2006116773A2 (en) * 2005-04-28 2006-11-02 The Regents Of The University Of California Methods, compositions, and compounds for modulation of monoacylglycerol lipase, pain, and stress-related disorders
CN101225085B (zh) * 2007-01-17 2011-09-21 天津天士力集团有限公司 苯基呋咱氮类一氧化氮供体型2-苯胺嘧啶衍生物、其制备方法、含有该化合物的组合物及其用途
TW201033163A (en) * 2008-10-20 2010-09-16 Sumitomo Chemical Co Method for manufacturing oxadiazolinone compound and intermediate thereof
WO2010074587A2 (en) 2008-12-23 2010-07-01 Bial - Portela & Ca., S.A. 5-o-substituted 3-n-aryl-1,3,4-oxadiazolones for medical use
WO2011108724A1 (ja) * 2010-03-04 2011-09-09 味の素株式会社 糖尿病又は肥満症の予防又は治療剤
US8501768B2 (en) * 2011-05-17 2013-08-06 Hoffmann-La Roche Inc. Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds
JP6007417B2 (ja) 2011-05-31 2016-10-12 レセプトス エルエルシー 新規ｇｌｐ−１受容体安定剤および調節剤
US8778923B2 (en) 2011-12-12 2014-07-15 Receptos, Inc. GLP-1 receptor modulators
WO2014201172A1 (en) 2013-06-11 2014-12-18 Receptos, Inc. Novel glp-1 receptor modulators
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
WO2015089137A1 (en) 2013-12-11 2015-06-18 Karos Pharmaceuticals, Inc. Acylguanidines as tryptophan hydroxylase inhibitors
WO2016015014A1 (en) 2014-07-25 2016-01-28 Receptos, Inc. Novel glp-1 receptor modulators
MX381977B (es) 2014-12-10 2025-03-13 Receptos Llc Moduladores del receptor de péptido 1 tipo glucagón.
WO2016109501A1 (en) 2014-12-30 2016-07-07 Karos Pharmaceuticals, Inc. Amide compounds as tryptophan hydroxylase inhibitors
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
CN108863774A (zh) * 2018-06-09 2018-11-23 石家庄市绿丰化工有限公司 一种2,4-二氯苯乙酰氯合成的方法
US11203597B2 (en) 2018-11-14 2021-12-21 Altavant Sciences Gmbh Crystalline spirocyclic compound, a dosage form containing, a method for using in treatment of disease, and a method for recrystallizing

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2299328A1 (fr) 1975-02-03 1976-08-27 Rhone Poulenc Ind Derives de l'alcoyloxy-5 phenyl-3 oxyde azo
US4076824A (en) 1975-02-03 1978-02-28 Rhone-Poulenc Industries Anthelmintic oxadiazolinone derivatives
FR2299028A1 (fr) 1975-02-03 1976-08-27 Rhone Poulenc Ind Nouvea
DK156439C (da) 1980-09-15 1990-01-22 Shell Int Research 7-substituerede 2,3-dihydrobenzofuranderivater samt pesticidpraeparater indeholdende disse og en fremgangsmaade til bekaempelse af skadelige organismer
EP0067471B1 (en) 1981-06-15 1985-11-06 Shell Internationale Researchmaatschappij B.V. 7-substituted 2,3-dihydrobenzofurans, their preparation and their use as pesticides or as chemical intermediates
US5236939A (en) 1989-09-23 1993-08-17 Bayer Aktiengesellschaft Substituted 1,3,4-oxa(thia)diazolinones process for their preparation and their use of combating endoparasites
DE3931843A1 (de) 1989-09-23 1991-04-04 Bayer Ag Substituierte 1,3,4-oxa(thia)diazolinone verfahren zu ihrer herstellung und ihre verwendung der bekaempfung von endoparasiten
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents

Also Published As

Publication number Publication date
WO2001066531A8 (de) 2002-07-25
PT1263745E (pt) 2004-09-30
EP1263745A1 (de) 2002-12-11
HK1054036A1 (en) 2003-11-14
IL151518A0 (en) 2003-04-10
HUP0302772A3 (en) 2007-03-28
AU3378701A (en) 2001-09-17
NO323483B1 (no) 2007-05-21
EP1263745B1 (de) 2004-05-19
RU2281283C2 (ru) 2006-08-10
CN1261419C (zh) 2006-06-28
ES2218383T3 (es) 2004-11-16
SK12752002A3 (sk) 2003-04-01
EE04877B1 (et) 2007-08-15
MXPA02008038A (es) 2004-04-05
DK1263745T3 (da) 2004-08-16
US20010031772A1 (en) 2001-10-18
NZ521207A (en) 2005-04-29
TR200401217T4 (tr) 2004-06-21
NO20024201L (no) 2002-09-03
HK1054036B (zh) 2006-11-17
CA2401953A1 (en) 2001-09-13
PL359702A1 (en) 2004-09-06
AR027611A1 (es) 2003-04-02
KR100790763B1 (ko) 2008-01-03
US6369088B2 (en) 2002-04-09
WO2001066531A1 (de) 2001-09-13
CN1416424A (zh) 2003-05-07
IL151518A (en) 2008-06-05
HRP20020732A2 (en) 2004-12-31
BR0108974A (pt) 2003-06-03
NO20024201D0 (no) 2002-09-03
KR20020079986A (ko) 2002-10-21
DE50102325D1 (de) 2004-06-24
HUP0302772A2 (hu) 2003-11-28
YU57802A (sh) 2005-07-19
AU784827B2 (en) 2006-06-29
JP2003525931A (ja) 2003-09-02
ATE267184T1 (de) 2004-06-15

Similar Documents

Publication Publication Date Title
EE200200498A (et) Asendatud 3-fenüül-5-alkoksü-1,3,4-oksadiasol-2-oon, selle valmistamine ja kasutamine hormoontundlikku lipaasi pärssivas ravimis ning seda sisaldav suhkurtõve ravim
EE200300145A (et) Asa- ja polüasanaftalenüülkarboksamiidid ja farmatseutiline kompositsioon
AU2002241538A1 (en) Intrasvascular drug delivery device and use therefor
EE200200201A (et) Trüosiinkinaasi pärssiv ühend, seda sisaldav farmatseutiline kompositsioon ning raviotstarbeline kasutamine.
EE05391B1 (et) Kompositsioon ja vahend selle transdermaalseks manustamiseks
IL143014A0 (en) Transdermal drug delivery and analyte extraction
EE200300240A (et) Arüülitud furaan- ja tiofeenkarboksamiid, seda sisaldav ravimpreparaat ning ühendi kasutamine kaaliumikanali blokaatorina toimiva ravimi valmistamiseks
EE05082B1 (et) Pürroolirea ühend, selle valmistamine ja kasutamine lipiidi- ja kolesteroolitaset alandava ravimi valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
AU6275601A (en) Stable polymeric micelle-type drug composition and method for the preparation thereof
DE60106489D1 (de) Zuckersubstituierte 2-azetidinone verwendbar als hypocholesterdenische arzneimittel
AU2001264887A1 (en) Drug delivery device
AU8654501A (en) Pulmonary drug delivery device
GB0123381D0 (en) Factor
AU3403201A (en) Drug delivery device and method
EE200200046A (et) 8-fenüül-6,9-dihüdro-[1,2,4]triasolo[3,4-i]puriin-5-ooni derivaat, selle valmistamine ja raviotstarbeline kasutamine ning seda sisaldav farmatseutiline kompositsioon
EE200100096A (et) Asatsüklilise tüvistruktuuriga tsükliline ühend, seda sisaldav farmatseutiline kompositsioon ning selle kasutamine ravimina
HUP0300048A3 (en) Transdermal or transmucosal dosage forms with a nicotine-containing active substance combination for smoker disintoxication and their use
AU2001275286A1 (en) Transdermal delivery
AU2002218502A1 (en) Lactam compounds and medicinal use thereof
EE200200109A (et) Asendatud 3-fenüül-5-alkoksü-1,3,4-oksdiasool-2-oon, selle valmistamine ja kasutamine lipaasi inhibiitorina ning seda sisaldav ravim
EE05415B1 (et) Ravimi manustamise vahend, eriti androgeenide manustamiseks
EE05168B1 (et) N-guanidinoalklamiid, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaat ning raviotstarbeline kasutamine
EE05406B1 (et) Memnopeptiidhend, selle valmistamine ja kasutamine ning seda sisaldav farmatseutiline kompositsioon
EE200200534A (et) Torasemiidi amorfne modifikatsioon, selle valmistamine ja kasutamine soolade saamiseks ning seda sisaldav farmatseutiline preparaat
EE200200440A (et) Estramustiinfosfaadi või selle metaboliidi kasutamine taksaani toimimisvõimet suurendava ravimi valmistamiseks, toimeaine ning seda sisaldav kombineeritud preparaat

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

MM4A Lapsed by not paying the annual fees

Effective date: 20090220